Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc....
November 06 2018 - 6:05AM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that it has appointed seasoned
biopharmaceutical executive Markus Warmuth, MD, to its Board of
Directors. Dr. Warmuth currently serves as an Entrepreneur in
Residence at the life science venture capital firm Third Rock
Ventures. He brings more than 20 years of drug discovery experience
and scientific acumen, with a strong focus on developing targeted
therapy and immune-oncology programs, to his new role on IMV’s
Board.
“Markus’s deep knowledge of targeted therapies and the
immune-oncology landscape, as well as his successful track record
of bringing the promise of advanced science to fruition in the
clinic, will be tremendous assets to IMV as he takes a seat on the
Board of Directors,” said Andrew Sheldon, Chairman of the Board at
IMV. “Having an experienced leader of his caliber is an optimal
addition to the IMV Board, and we look forward to leveraging his
counsel and insights as IMV advances its own science-driven
immuno-oncology pipeline.”
Prior to his role at Third Rock, Dr. Warmuth spent seven years
as the Chief Executive Officer of H3 Biomedicine, a
biopharmaceutical company that specializes in the discovery and
development of precision oncology treatments. While at H3, he was
instrumental in the company’s successful progress from a drug
discovery engine to a clinical stage organization with a
specialized focus on genomics-based oncology drug candidates and
novel immune-oncology approaches. Previous to his role at H3, he
served in various positions of increasing responsibility at the
Novartis Institute for Biomedical Research (NIBR) and the Genomics
Institute of the Novartis Research Foundation (GNF), including as
the Director of Kinase Biology and Head of Oncology Pharmacology.
In these roles, he focused on developing data-driven, science-based
drug discovery programs, with a specialization in novel anti-cancer
therapies.
“Complex diseases like cancer need solutions based on
fundamentally sound science, a willingness to collaborate, and
experienced leadership,” stated Dr. Warmuth. “I believe that IMV is
well positioned to be a significant force in advanced
immuno-oncology drug development and I am looking forward to
working with my fellow Board members, the leadership team under the
helm of CEO Fred Ors, and the rest of the IMV staff to help bring
the potential benefits of immuno-oncology to more patients and
underserved disease markets.”
Dr. Warmuth earned his MD from Ludwig Maximilian University, in
Munich, Germany. He joins the Board of Directors at IMV as current
board member Alfred Smithers, President and Chief Executive Officer
of Iona Resources Holdings Limited, departs.
“Alfred has been a long-time supporter of IMV and an important
pillar of the Company’s Board for many years,” commented Mr.
Sheldon. “We are incredibly grateful for his time and support and
wish him well on his future endeavors.”
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical
stage biopharmaceutical company dedicated to making immunotherapy
more effective, more broadly applicable, and more widely available
to people facing cancer and other serious diseases. IMV is
pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology
leverages a novel mechanism of action that enables the programming
of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac as a combination therapy in
multiple clinical studies with Incyte and Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024